Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (151)	12/22/2001 8:41:52 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 897

The Barron's article had some comments on GENZ: "Genzyme, at 60, doesn't look much better. It trades for about 50 times this year's projected profits, and it's reliant for the bulk of its growth on a single drug, Renagel. The company's biggest-selling product, Cerezyme, a treatment for Gaucher's disease, an inherited disorder, has started to plateau and faces potential competitive threats. One new Genzyme drug, Fabrazyme, for treatment of Fabry disease, another inherited condition, faces an uphill fight against a rival drug from TranskaryoticTherapies, whose treatment has shown superior clinical-trial results." ij PS. Since many of us are overweighted in biotechs, a suitable list of shorts would make for a good hedge expecially when the sector has had a nice run. Thanks - good idea.